Halozyme Therapeutics, Inc.

Healthcare

NASDAQ:HALO · NASDAQ Global Select

Market Cap $8.39B Beta 0.87 P/E (TTM) 23.6

$69.50 -1.46%

-$1.03 today

52W Low $51.06High $82.22

Vol 1.04M · Avg 1.63M

EPS (TTM)$2.95

Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+28.75%

Period High

$81.23

Period Low

$52.02

Latest

$69.50

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Jazz Pharmaceuticals plc

NASDAQ:JAZZ

$14.66B

Henry Schein, Inc.

NASDAQ:HSIC

$9.31B

Corcept Therapeutics Incorporated

NASDAQ:CORT

$8.92B

Cytokinetics, Incorporated

NASDAQ:CYTK

$8.72B

AptarGroup, Inc.

NYSE:ATR

$7.51B

Merus N.V.

MRUS

$6.83B

Grifols, S.A.

NASDAQ:GRFS

$6.50B

Abivax S.A.

NASDAQ:ABVX

$6.35B

Rhythm Pharmaceuticals, Inc.

NASDAQ:RYTM

$6.05B

Caris Life Sciences, Inc.

NASDAQ:CAI

$5.07B

What is the latest HALO filing?

The latest filing shown is 3 dated Jun 9, 2026.

How many recent filings does HALO have?

Intrinsic Alpha currently shows 20 recent filings for HALO.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.